MMG Partners with Remedy Health Media to Bolster Clinical Trial Enrollment
MMG
, a global health communications company specializing in clinical trial patient recruitment and retention, has formed an exclusive partnership with
Remedy Health Media
to deliver access to a larger pool of qualified potential clinical trial participants. Remedy Health Media (Remedy) is a health information and technology company, which produces a variety of clinical and wellness resources including Remedy’s Healthy Living and Diabetes Focus and maintains publishing partnerships with globally recognized institutions such as Johns Hopkins Medicine and the University of California, Berkeley School of Public Health.
This partnership offers value to MMG’s clients by effectively reaching their desired audiences through Remedy’s community of more than 150 million health-information-seeking patients and caregivers. Remedy’s 28.4 million unique monthly visitors (comScore, September 2012) proactively seek treatment options for therapeutic areas that match MMG’s category coverage.
Additional benefits for MMG’s clients include:
· Guaranteed increase in already-high number of patient referrals;
· Strengthened patient retention rate through Remedy’s HIPAA-compliant, proprietary mobile content and adherence tools; and
· Exclusive media placement capabilities.
“We were drawn to this partnership with Remedy because we want to be able to provide information to patients faster while offering our clients even higher value for their investment,” said John Benbrook, CEO of MMG. “We look forward to leveraging MMG’s unique presence within Remedy’s expansive network of trusted health resources to deliver even greater measurable results.”
Michael Cunnion, CEO of Remedy Health Media, said, “We’re thrilled to partner with MMG because this is a perfect opportunity to provide better information, tools and connectivity to patients who are actively seeking clarity in the trial enrollment process.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
